Phase II study of marqibo in patients with metastatic uveal melanoma

Objective

This is a clinical trial of marqibo that will be given through intravenous (I.V.) infusion. Marqibo is investigational.

IRB Protocol Number

08-0522

Principal Investigator(s)

RENE GONZALEZ

Cancer Trials

• Melanoma (Except Eye)

Sponsor(s)

HANA biosciences

Contact

DIANA MORALES at 720-848-0632
or DIANA.MORALES@UCDENVER.EDU

Eligibility and Other Participant Information

What To Expect : A screening period to determine eligibility. A treatment period that can last as long as you are benefitting from the investigational drug. A follow up period will consist of a phone call once every 3 months. // Eligibility criteria include but are not limited to 18 years or older with metastatic uveal (ocular) melanoma.